Favorable effects of long-term therapy with gonadoliberin analogues in three patients with advanced and recurrent ovarian cancer.
Eur J Gynaecol Oncol
; 30(5): 589-91, 2009.
Article
em En
| MEDLINE
| ID: mdl-19899425
ABSTRACT
BACKGROUND:
Numerous scientific reports indicate a high possibility of gonadotrophin involvement in ovarian cancer neoplasia. CASE PRESENTATION In a 49-year-old patient with recurrent ovarian cancer, a present survival of ten years has been achieved. She has been using GnRH analogues for nine years. A 32-year-old patient with a primary highly advanced ovarian cancer received standard therapy and additional implants with GnRH analogues as consolidation therapy for 20 months. Overall survival is 14 years. In a 56-year-old patient with advanced ovarian cancer GnRH analogues were used as consolidation therapy for seven years, achieving seven years of a complete clinical remission and nine and a half years of survival up to now.CONCLUSION:
It seems that gonadoliberin analogues should find their place in ovarian cancer therapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Adenocarcinoma Papilar
/
Hormônio Liberador de Gonadotropina
/
Cistadenoma Seroso
/
Antineoplásicos Hormonais
/
Recidiva Local de Neoplasia
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Eur J Gynaecol Oncol
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Polônia